Virginia is currently home to 1824 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Richmond, Charlottesville, Norfolk and Fairfax. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
A Prospective, Clinical Investigation of the Vanguard 360 Revision Knee
NCT01542580
Recruiting
The purpose of this study is to evaluate performance of the Vanguard 360 revision knee system utilizing offset on either the tibial component, femoral component, or both in terms of the restoration of mechanical alignment, clinical outcomes and survivorship.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/20/2025
Locations: OrthoVirginia West End Orthopedic Clinic, Richmond, Virginia
Conditions: Osteoarthritis, Rheumatoid Arthritis, Traumatic Arthritis, Post Traumatic Deformity, Complications; Arthroplasty, Deformity of Limb
Register for Updates
Remotely Monitored Exercise Interventions in Patients with MCSPC Undergoing ADT (Prostate 006)
NCT06429813
Recruiting
This study consists of two home-based exercise programs: a stationary exercise bicycle intervention (Arm A), and a walking intervention (Arm B). The study will enroll 24 patients who are starting ADT (Androgen Deprivation Therapy)/ARSI (Androgen-Receptor Signaling Inhibitors) therapy for newly diagnosed metastatic castrate-sensitive prostate cancer (mCSPC). All participants will be asked to complete 1-2 training sessions at UVA prior to starting the exercise. All participants will be asked to co... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
02/19/2025
Locations: University of Virginia, Charlottesville, Virginia
Conditions: Castrate Sensitive Prostate Cancer, Metastatic Prostate Cancer
Register for Updates
Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2
NCT05911295
Recruiting
This study will enroll participants with urothelial cancer (UC). UC can include cancer of the bladder, kidney, or the tubes that carry pee through the body (ureter, urethra). This study will try to find out if the drugs disitamab vedotin with pembrolizumab works better than platinum-containing chemotherapy to treat patients with UC. This study will also test what side effects happen when participants take these drugs together. A side effect is anything a drug does to the body besides treating th... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/19/2025
Locations: Inova Schar Cancer Institute, Fairfax, Virginia
Conditions: Urothelial Carcinoma
Register for Updates
Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors
NCT05887492
Recruiting
The goal of this interventional clinical trial is to learn about TNG260, a CoREST inhibitor, in combination with pembrolizumab in patients with advanced solid tumors with a known STK11 mutation. The main question\[s\] it aims to answer are: * the recommended dose for Phase 2 * to evaluate the safety and tolerability of the combination therapy * to determine the pharmacokinetics of TNG260 * to evaluate the initial antineoplastic activity Participants will receive study treatment until they exp... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/19/2025
Locations: NEXT Oncology Virginia, Fairfax, Virginia
Conditions: Non Small Cell Lung Cancer, Solid Tumors, Adult, Endometrial Cancer, Pancreatic Cancer, Cervical Cancer, Breast Cancer, Carcinoma of Unknown Primary
Register for Updates
Intramedullary Calcium Sulfate Antibiotic Depot
NCT05766670
Recruiting
The goal of this randomized clinical trial is to study the best treatment for open lower leg fractures to prevent infection. The main questions it aims to answer is if treating tibia fracture patients with a calcium sulfate antibiotic depot is better at preventing infection that the standard of care.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/19/2025
Locations: Valley Health, Winchester, Virginia
Conditions: Open tíbia Fracture, Osteomyelitis Tibia, Tibial Fractures
Register for Updates
Phase 1/2 Study to Evaluate Vosilasarm (EP0062) as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer
NCT05573126
Recruiting
The aim of this study is to identify the optimal dose for Vosilasarm (EP0062) as monotherapy and in combination with standard-of-care therapies to assess its Safety, Tolerability, Pharmacokinetics, and Efficacy in Patients with Relapsed Locally Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
02/19/2025
Locations: Virginia Cancer Specialists, Fairfax, Virginia
Conditions: Hormone Receptor-positive Breast Cancer, Hormone Receptor Positive HER-2 Negative Breast Cancer, Metastatic Breast Cancer
Register for Updates
4D-710 in Adult Patients With Cystic Fibrosis
NCT05248230
Recruiting
This is a Phase 1/2 multicenter, open-label, single dose trial of 4D-710 investigational gene therapy in adults with cystic fibrosis.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/19/2025
Locations: Virginia Commonwealth University Health System, Richmond, Virginia
Conditions: Cystic Fibrosis Lung
Register for Updates
Cardioprotection in AML
NCT04977180
Recruiting
Patients with acute myeloid leukemia (AML) often receive a drug called daunorubicin. Daunorubicin is a type of drug called an anthracycline, which increases the risk of some damage to the heart. Beta blockers and angiotensin-converting enzyme inhibitors (ACEi) are two types of drugs that are often used (and are FDA approved) to treat the type of damage to the heart caused by anthracyclines. They have also been used in some populations to prevent this type of heart damage. In this study, particip... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/19/2025
Locations: University of Virginia, Charlottesville, Virginia
Conditions: AML, Acute Myeloid Leukemia
Register for Updates
PROGRESS: Management of Moderate Aortic Stenosis by Clinical Surveillance or TAVR
NCT04889872
Recruiting
This study objective is to establish the safety and effectiveness of the Edwards SAPIEN 3 / SAPIEN 3 Ultra / SAPIEN 3 Ultra RESILIA Transcatheter Heart Valve systems in subjects with moderate, calcific aortic stenosis. Following completion of enrollment, subjects will be eligible for enrollment in the continued access phase of the trial.
Gender:
ALL
Ages:
65 years and above
Trial Updated:
02/19/2025
Locations: Kaiser Mid Atlantic, McLean, Virginia
Conditions: Aortic Stenosis, Calcific, Aortic Valve Stenosis
Register for Updates
Real-world Experience of Catheter Ablation for the Treatment of Paroxysmal and Persistent Atrial Fibrillation
NCT04088071
Recruiting
The primary purpose of this registry is to obtain real-world clinical experience of Paroxysmal (PAF) and Persistent (PsAF) Atrial Fibrillation ablation radiofrequency (RF) technologies. Data from the registry will be used to assess clinical outcomes, including procedural efficiency, safety, and long-term, effectiveness of catheter ablation with novel RF technologies in PAF and PsAF patients.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/19/2025
Locations: Centra Health, Inc. dba Stroobants Cardiovascular Center, Lynchburg, Virginia
Conditions: Paroxysmal Atrial Fibrillation, Persistent Atrial Fibrillation
Register for Updates
A Study to Evaluate BMS-986470 in Healthy Volunteers and Participants With Sickle Cell Disease
NCT06481306
Recruiting
The purpose of this study is to evaluate the safety and tolerability, pharmacokinetics and pharmacodynamics, pH and food effect, and preliminary efficacy of BMS-986470 in healthy volunteers and participants with sickle cell disease.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/18/2025
Locations: Local Institution - 0013, Fairfax, Virginia
Conditions: Anemia, Sickle Cell, Healthy Volunteers
Register for Updates
Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)
NCT06291376
Recruiting
The primary objective of this study to evaluate efficacy of ravulizumab compared with placebo on proteinuria reduction and change in eGFR in adult participants with IgAN who are at risk of disease progression.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/18/2025
Locations: Research Site, Charlottesville, Virginia
Conditions: Immunoglobulin A Nephropathy, IgAN
Register for Updates